Genmab (GMAB) said Sunday that results from a phase 1b/2 trial of its experimental epcoritamab treatment in combination with other drugs in patients with relapsed/refractory diffuse large B-cell lymphoma showed an overall response rate of 87%.
The results cover patients who are eligible for autologous stem cell transplantation.
The company said results also showed a complete response rate of 65%, and a partial response rate of 23%.
Safety data from the trial showed a low-grade cytokine release syndrome and no discontinuations due to treatment-emergent adverse events, Genmab said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.